Emergent BioSolutions
400 Professional Drive
Suite 400
Gaithersburg
Maryland
20879
United States
Tel: 240-631-3200
Fax: 240-631-3203
Website: https://www.emergentbiosolutions.com/
About Emergent BioSolutions
Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030. For more information visit www.emergentbiosolutions.com. Find us on LinkedIn and follow us on Twitter.
Stock Symbol: EBS
567 articles about Emergent BioSolutions
-
Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)
11/28/2023
Emergent BioSolutions Inc. (NYSE: EBS) today announced that the Biomedical Advanced Research and Development Authority (BARDA) within the Administration for Strategic Preparedness and Response at the United States Department of Health and Human Services has awarded a $75 million option to Emergent’s existing contract (HHSO100201600030C) for the acquisition of newly licensed anthrax vaccine CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted).
-
Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing
11/24/2023
Emergent BioSolutions Inc. (NYSE: EBS) today confirmed that on November 16, 2023, the New York Stock Exchange (NYSE) sent a notice that the company is not in compliance with Section 802.01E of the NYSE Listed Company Manual due to a delay in filing its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023.
-
Emergent BioSolutions Reports Third Quarter 2023 Financial Results
11/8/2023
Emergent BioSolutions Inc. (NYSE: EBS) today reported selected financial results for the third quarter ended September 30, 2023.
-
October saw a surge of life science job activity with job applications up 65% from last year as well as a number of a significant layoff announcements.
-
UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023
10/30/2023
Emergent BioSolutions Inc. has rescheduled its conference call to Wednesday, November 8, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2023, recent business developments, and financial outlook for full year 2023.
-
Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 2, 2023
10/19/2023
Emergent BioSolutions Inc. will host a conference call on Thursday, November 2, 2023, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2023, recent business developments, and financial outlook for full year 2023.
-
Emergent BioSolutions’ NARCAN® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency
8/30/2023
Emergent BioSolutions Inc. announced NARCAN® Naloxone HCl Nasal Spray 4 mg will be available on shelves nationwide and online beginning in September.
-
Emergent BioSolutions Reports Financial Results for Second Quarter 2023
8/8/2023
Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2023. It also announced strategic steps to reduce investment in and de-emphasize focus on growth in its CDMO business.
-
Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position
8/8/2023
Emergent BioSolutions (NYSE: EBS) today announced it is reducing investment in and de-emphasizing focus on growth in its CDMO services business.
-
Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola
7/31/2023
Emergent BioSolutions Inc. announced that it was awarded a 10-year contract by the BARDA, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, valued at up to a maximum of $704 million, for advanced development, manufacturing scale-up, and procurement of Ebanga™, a licensed treatment for Ebola virus disease.
-
Emergent BioSolutions to Release Second Quarter 2023 Financial Results and Conduct Conference Call on August 8, 2023
7/25/2023
Emergent BioSolutions Inc. will host a conference call on Tuesday, August 8, 2023, at 5:00 pm eastern time to discuss the financial results for the second quarter of 2023, recent business developments, revenue guidance for the third quarter of 2023, and financial outlook for full year 2023.
-
Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
7/20/2023
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) has approved CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when administered in conjunction with recommended antibacterial drugs.
-
Emergent BioSolutions Announces CEO Transition
6/27/2023
Emergent BioSolutions (NYSE: EBS, “Emergent” or the “Company”) today announced that Robert G. Kramer Sr. has informed the Board of Directors of his intention to retire from Emergent.
-
Emergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian Nordic
5/15/2023
Emergent BioSolutions announced it has completed the sale of its travel health business to Bavarian Nordic.
-
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 25, 2023 at 9:00am EDT
5/11/2023
Emergent BioSolutions Inc. announced that its 2023 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 25, 2023 at 9:00 AM EDT.
-
Emergent BioSolutions Reports Financial Results For First Quarter 2023
5/9/2023
Emergent BioSolutions Inc. reported financial results for the first quarter ended March 31, 2023.
-
Emergent BioSolutions to Release First Quarter 2023 Financial Results and Conduct Conference Call on May 9, 2023
4/19/2023
Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, May 9, 2023, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2023, recent business developments, revenue guidance for the second quarter of 2023, and financial outlook for full year 2023.
-
U.S. FDA Approves Over-the-Counter Designation for Emergent BioSolutions’ NARCAN® Nasal Spray, a Historic Milestone for the Opioid Overdose Emergency Treatment
3/29/2023
Today, Emergent BioSolutions Inc. (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has approved NARCAN® Naloxone HCl Nasal Spray 4 mg as an over-the-counter (OTC) emergency treatment of opioid overdose.
-
The FDA is expected to make decisions on Emergent BioSolutions' sNDA for OTC Narcan and Roche's Polivy in frontline DLBCL.
-
Emergent BioSolutions Reports Financial Results for Fourth Quarter 2022
2/27/2023
Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the fourth quarter and year ended December 31, 2022.